drugset / Trial / NCT05961696
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
To find a recommended dose of mosunetuzumab that can be given to patients with ALL.
Timeline
- Start
- 2023-07-05
- Primary completion
- 2023-10-03
- Completion
- 2023-10-03
Outcome
Outcome not reported
Stopped (Enrollment): “0 accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |